In this paper, we propose an optimal control approach for adequate therapeutic strategy design for HIV infection. Starting from a system of ordinary differential equations modeling the human immunodeficiency virus (HIV) infection and its interaction with the immune system, we introduce first a control representing a treatment using highly active antiretroviral therapy (HAART), then we introduce a control characterizing a combination treatment of both highly active antiretroviral therapy (HAART) and immunotherapy using the Interleukin-2. A comparison of the results allows us to choose which treatment strategy is able to reduce the viral load and the side effects, maximize the immune response level and the number of healthy CD4 + T-cells while minimizing the cost of treatment. The Pontryagin's maximum principle is used to characterize the optimal controls. The optimality system is derived and solved numerically using an iterative method with a Runge-Kutta fourth order scheme.
Introduction
In recent decades, the AIDS has generated much interest among scientists in general and more precisely mathematicians. For over 20 years, many scientists have focused on this disease and several mathematical models have been proposed in order to better understand the disease and try to find a proper treatment that minimizes the viral load, side effects and the cost of treatment.
Mathematical models proposed by Arnaout, Wodarz and Nowak [1] show that people with AIDS who are able to maintain a high level of CTL cells remain healthy longer hence the importance of the action of CTL cells in a possible treatment. Other models such as Kirschner and Webb [7] are based on the immunotherapy using the Interleukin-2 (IL-2) which is a type of cytokine that stimulates lymphocyte proliferation and immune response and it's necessary for the growth, proliferation and differentiation of T-cells to become 'effector' T-cells. They developed a mathematical model of dynamics of disease progression and IL-2 treatment of the HIV-infected immune system. Their model is based upon the key markers of HIV progression, CD4
+ T-cells level and viral levels in the plasma, and the model agrees with preliminary results from clinical trials. They also predict that immunotherapy administered during the early stages of disease progression is most beneficial for raising CD4 + T-cells count. Some authors have proposed mathematical models of HIV treatment using the optimal control theory. Kirschner, Lenhart and Serbin [6] have established optimal regimens for a scenario in which the treatment reduces the viral production rate. However Fister, Lenhart and McNally [4] have established results for a similar model to that discussed in [6] but by introducing a control represented by a drug that reduces the infectivity rate. In these last two models of HIV treatment, the optimal controls were generally monotonous and decreasing.
In the study [5] , the patients with less than 200 healthy CD4 + T-cells per mm −3 day −1 who received low doses of Interleukin-2 less than 12, 500 IU per day, their CD4 + T-cells level declined however the other patients who received a maximal nontoxic tolerated dose of IL-2 in the range of 187, 000-250, 000 IU per day, their CD4 + T-cells level increased with a mean monthly gain of 27 units of healthy CD4
+ T-cells per micrometer of blood and per month. Other clinical studies [11] have demonstrated that exogenous human recombinant IL-2 can be safely administered concurrently with potent antiretroviral therapy to HIV-infected patients. These studies also provide that therapeutic immunization in the presence of HAART may be more effective.
Among those different studies, the basic virus infection model (BVIM) introduced by Priti Kumar Roy and Amar Nath Chatterjee [10] is widely used in studies of virus infection dynamic. This model typically considered uninfected (x) and infected (y) CD4
+ T-cells and the immune response (z) measured by the rate of the CTL immune cells. The dynamics of BVIM are governed by the following equations:
where the parameters model are defined in the following section of our work. In this work we take the basic virus infection model (1) appeared in [10] in which we will introduce optimal controls characterizing different treatments. This paper is organized as follows: Section 2 describes mathematical models of HIV with control terms, the first part presents a treatment using highly active antiretroviral therapy, and the second one presents a treatment using a combination of both highly active antiretroviral therapy and immunotherapy. The analysis of optimization problems is also presented in the same section. In section 3, we present the numerical iterative method used and the simulations corresponding results and we discuss the numerical results obtained in this paper while comparing them with other results established in similar works. Finally we compare the results of these two therapeutic approaches in conclusion in section 4.
2 Mathematical models 2.1 Therapeutic approach using highly active antiretroviral therapy (HAART)
Presentation of the model without HIV treatment
Here we introduce the ODE modeling of the immune dynamics of an HIVinfected immune system (1). We note that these equations model an untreated individual, treatment will be introduced in the next subsection via an optimal control. For analysis of the system, we will be forced to link this system to the following initial conditions:
3 ) be the Banach space of continuous functions mapping the interval [0, T ] into IR 3 with the topology of uniform convergence. It easy to show that there exists a unique solution (x(t), y(t), z(t)) of system (1) with initial data (x 0 , y 0 , z 0 ) ∈ C. In addition, for biological reasons, we assume that the initial data for system (1) satisfy:
The definitions and descriptions of above model parameters (1) Number of CD4 + T cells after a maximum proliferation Table 1 : The description of parameters used.
Presentation of the model with HIV treatment.
In this section, we introduce a control u that characterizes the treatment to the above mentioned model (1) . The control u(t) represents the efficiency of the highly active antiretroviral therapy (HAART) in inhibiting viral production for reducing the viral load and the infection level. Our HIV model is given by the following system of ordinary differential equations:
Our goal is obviously to try to maximize the levels of healthy CD4 + T cells as well as the immune response for reducing the infection rate and subsequent the viral load while minimizing the cost of treatment. Our control is a function u(t) taking values between 0 and 1 : u(t) = 1 represents a completely effective highly active antiretroviral therapy, while u(t) = 0 represents no treatment.
The optimal control problem.
The problem is to maximize the objective functional:
where the parameter A ≥ 0 is based on the benefits and costs of the treatment.
Since our optimal control is primarily designed to reduce the rate of viral replication and therefore the most logical is to multiply the term 'βxy' by (1 − u) . In our case the constant 'β' represents both the rate of cell infection and the rate of viral replication that may well give us a pretty clear idea about drugs to prescribe. Our target is to maximize the objective functional defined in equation (4) by increasing the number of the uninfected cells, maximizing immune response by CTLs, decreasing the viral load and minimizing the cost of treatment. In other words, we are seeking an optimal control u * ∈ U such that:
where U is the control set defined by
The Pontryagin's maximum principle [12] provides necessary conditions for an optimal control problem. This principle converts into a problem of maximizing the Lagrangian L, pointwisely with respect to u:
The ψ j where j = 1, 2, 3 are our adjoint variables that determine the adjoint system which satisfies the optimality necessary conditions. By applying the Pontryagin's maximum principle [9] and the existence result for the optimal control from [13] , we obtain the following theorem: Theorem 2.1 Given optimal control u and solutions x, y and z of the corresponding state system (3) , there exists adjoint variables ψ 1 , ψ 2 and ψ 3 satisfying the following equations:
with transversality conditions
Moreover, the optimal control is given by:
Proof. Due to the convexity of integrand of J with respect to u, a priori boundedness of the state solutions and the Lipschitz property of the state system with respect to the state variables. The existence of an optimal control has been given by [10] (see Corollary 4.1). The adjoint equations and transversality conditions can be obtained by using Pontryagin's maximum principle such that:
The optimal control u * can be solve from the optimality conditions:
By the bounds in U of the control, it is easy to obtain u * in the form of (7).
2.2 Therapeutic approach using a combination treatment of both HAART and Immunotherapy.
Presentation of the model with HIV treatment.
In this section, we introduce a control u=(u 1 ,u 2 ) to the above mentioned model (1). The control u 1 (t) represents the efficiency of the highly active antiretroviral therapy (HAART) in inhibiting viral production for reducing the viral load and the infection level, and the control u 2 (t) represents the efficiency of the immunotherapy (using Interleukin-2) in stimulating immune response for restoring immune defenses. Our HIV model is given by the following system of ordinary differential equations:
where x(0)=x 0 , y(0)=y 0 , z(0)=z 0 are given and the definitions of above model parameters have been previously defined. The control functions: u 1 (t) and u 2 (t), are bounded and Lebesgue integrable functions. The control u 1 (t) is a function with values normalised to be between 0 and 1: u 1 (t)=1 represents a completely effective highly active antiretroviral therapy, while u 1 (t)=0 represents no treatment. Since u 1 (t) is primarily designed to reduce the rate of viral load and therefore the most logical is to multiply the term 'βxy' by (1 − u) since 'β' represents both the rate of cell infection and the rate of viral replication. The control u 2 (t) is a function with values normalised to be between 0.0001 and 0.003: u 2 (t)=0.0001 for the low dose patients and u 2 (t) = 0.003 for the maximal tolerated nontoxic dose that will produce the desired effect without unacceptable toxicity [5] .
The optimal control problem.
where the parameters A 1 ≥ 0 and A 2 ≥ 0 are based on the benefits and costs of the treatment. Our target is to maximize the objective functional defined in equation (10) by increasing the number of the uninfected target cells, maximizing immune response, decreasing the infection level and minimizing the cost of treatment. In other words, we are seeking optimal control pair (u * 1 , u * 2 ) such that:
The Pontryagin's maximum principle [9] provides necessary conditions for an optimal control problem. This principle converts into a problem of maximizing the Lagrangian L, pointwisely with respect to u 1 and u 2 :
The ψ j where j = 1, 2, 3 are our adjoint variables that determine the adjoint system which satisfies the optimality necessary conditions. By applying the Pontryagin's maximum principle [9] and the existence result for the optimal control from [13] , we obtain the following theorem: 
and u * 2 (t) = min(0.003, max(0.0001,
Proof. Due to the convexity of integrand of J with respect to u, a priori boundedness of the state solutions, and the Lipschitz property of the state system with respect to the state variables. The existence of an optimal control has been given by [13] (see Corollary 4.1). The adjoint equations and transversality conditions can be obtained by using Pontryagin's maximum principle such that:
The optimal controls u * 1 and u * 2 can be solve from the optimality conditions:
By the bounds in U of the controls, it is easy to obtain u * 1 and u * 2 in the form of (13) and (14), respectively.
Numerical Simulation

Summary of parameters and values used
A wide range of values is proposed for modeling of HIV infection in the presence the immune response compartment [1] . We specify that the detailed description of the parameters is given above in the presentation of the model without HIV treatment and we note that HIV-specific parameters are given in units of cells per mm −3 day −1 . We can say that it is difficult to assign a set of parameters to persons with different clinical outcomes. However, since the interest is due to the initiation of any treatment by the introduction of an optimal control in the ODE system (1), we keep the values of the parameters found in [10] and we state that the stability properties of the model are stored for these parameters which have rearranged in the following We note that the period of the therapy considered is T =600 days, it's the necessary observed period which allows us to obtain good results.
Numerical results
To solve numerically this problem, namely to find an optimal control u * that maximizes the objective function J(u), many methods and techniques of programming can be used. The method we chose for solving the optimality system optimally is generally known under the name of 'Forward Backward Sweep Method' [12] . The optimality system is solved using an iterative method with a Runge-Kutta fourth order scheme. The state system with an initial guess is solved forward in time and then the adjoint system is solved backward in time. The iterations continue until convergence is achieved. Finally, we note that all informations about the convergence of this method is given in [8] .
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Figure 1:
The Optimal control u * (t).
Figure 2: The graphics of the states x(t), y(t) and z(t) before and after treatment with (x(0)=50mm
As is shown in Figure 2 , we find that following the initial values of healthy and infected CD4
+ T-cells and CTL immune cells, the patient in question in this HIV mathematical model is in AIDS stage, this phase is characterized by the weakening of the immune system and the development of all kinds of opportunistic infections that take advantage of the weakness of the immune system to invade the body. Generally during this period of the disease, the rate of healthy CD4 + T-cells is less than 200 mm −3 day −1 [3] .
Taking into account these facts and characteristics of the disease in AIDS stage, our optimal control starts at a maximum value near u = 0.94, which corresponds to a complete treatment of highly active antiretroviral therapy (Figure 1 ). Subsequently and after an initial decline that will last for the first 30 days of treatment, the optimal control reaches a value u = 0.69 then the treatment rises during the next 40 days and stabilizes from the 70th day at the value u = 0.93 and then keeps a constant value. Our optimal control eventually falls sharply to the value u = 0 at the end of the treatment period and more precisely from the 565th day.
Early findings graphs (Figure 2 ) lead us to say that our optimal treatment protocol has a very beneficial effect on the population of healthy CD4
+ T-cells that reaching maximum values more than 1200 mm −3 day −1 throughout most of the duration of treatment lasting 600 days. As the results in [1] , although HIV does not target the CTLs directly, it has been noted clinically for some time that individuals who maintain a high level of CTLs remain healthy longer. Despite the fact that the infection isn't eradicated during the treatment period, but it reached very low levels less than 10 mm −3 day −1 , we simply note that a significant growth of the infection was observed towards the end of treatment, followed by a drop in the population of healthy CD4
+ T-cells and a maximum stimulation of immune response, this increase in the level of infection is very logical and normal at that stage of the disease and after a sudden interruption of the treatment acting mainly on viral load. We also note that the increase in the level of infection is followed immediately by a corresponding increase of the natural immune response that eliminates infected CD4
+ T-cells.
The sudden and severe decrease in the level of our optimal control in the last 35 days of treatment logically implies a significant increase in the level of infection, which leads to a considerable drop in the level of healthy CD4 + Tcells especially for patients in AIDS stage. But in parallel, we note with great interest the maximum growth of immune response and significant stimulation of CTL in the period following the increase in the viral load level. It's also noted that the population of healthy CD4
+ T-cells is around 500 units per microliter of blood towards the end of the treatment period, which is significantly higher than the initial level that didn't exceed 50 units per microliter of blood. We finally concluded that the immune system at this stage of HIV infection is still able to reduce and stabilize the viral load and partially restore the immune response system. By studying the shape of our optimal control's graph (Figure 1) , we note the initial decrease of the treatment with great interest, this happens at the same time as the growth of the immune response, we can deduce that during periods when the immune response is effective, the recourse to treatment acting on viral load is less necessary because at this time, the immune system plays its role perfectly in controlling the disease.
After comparing our results with those established in [6] and [4] , we find that our optimal control behaves differently from controls used in models that don't present explicitly a compartment of the immune response. In [6] , the optimal control was either monotonically decreasing from its maximum value or peaked just after the start of treatment and then declined thereafter.
However, we observe that the behavior of our optimal control takes into account the evolution of the disease and the level of infection in every moment of the treatment period and acts according to these circumstances by adopting optimal strategies specific to each situation corresponding such as the increase or the decrease of the treatment regimen. We believe that the decline of treatment depends mainly on immune stimulation and action of the immune response via the CTL immune cells, thus our optimal treatment is reduced over a period of time while the immune response takes over. Any subsequent increase in the level of treatment is considered after the sudden reappearance of the disease disorders characterized by an increase in viral load. And finally maintaining a constant optimal control for any period is recommended to consolidate the treatment and cope with the instability of the HIV infection at this stage of the disease.
Therapeutic approach using a combination treatment of both
HAART and Immunotherapy. Figure 3: The graphics of the optimal controls u * 1 (t) and u * 2 (t).
As is shown in Figure 3 , we note with interest a decrease in the concentration of the antiretroviral therapy after the introduction of new combination treatment of both HAART and immunotherapy especially during the first four months of treatment. Taking into account the initial values of x(t), y(t) and z(t) and the characteristics of the AIDS stage, as was the case in some studies [5] , our optimal treatment strategy adopts a control representing immunotherapy by means of a model of daily injections of IL-2 where the treatment function u 2 (t) is taken to be constant assuming the treatment can be approximately by a continuous process where u 2 = 0.00290625. However, the control u 1 (t) that represents the HAART begins with a minimum value u 1 = 0.05 and increases progressively to reach its maximum value u 1 = 0.93 from the 200th day, then the control remains constant until the 585th day when it drops sharply and reaches the value u 1 = 0 at the end of the treatment period.
Compared with the optimal treatment using the HAART (Figure 3 ), we note with interest that the introduction of an optimal combination treatment of HAART and immunotherapy allows us to reduce the concentration of the antiretroviral therapy during the first 200 days and keep a maximum level of healthy CD4
+ T-cells and a very low level of infection even at the end of the treatment.
The introduction of immunotherapy using the Interleukin-2 administered to AIDS patients under the highly active antiretroviral therapy (HAART) has enabled us to achieve all the goals we set in the optimal control problem (Figure 4) , throughout the duration of treatment, which lasts 600 days, we were able to keep a high level of immune response that allowed us to maximize the population of healthy CD4 + T-cells more than 1200 mm −3 day −1 and even if the infection is not totally eradicated but it reached very low levels less than 20 mm −3 day −1 and it didn't rise at the end of the optimal treatment which obviously would alleviate the antiretroviral therapy and subsequently reduce the side effects. We finally concluded that the implementation of treatments that stimulate the immune response is very beneficial as a complement to the HAART treatment.
Conclusion
In order to get the most optimal treatment for HIV infection in AIDS stage, firstly, we adopted a therapeutic strategy that aims to introduce a control characterizing HAART and we obtained thereafter very good results by maximizing the level of the immune response and the number of healthy CD4 + T-cells and minimizing the level of infection and the cost of treatment but we note however that from the moment when the control decreases towards the end of the treatment period, the level of infection increases sharply which leads subsequently a declining in the population of healthy CD4
+ T-cells. Taking into account these results and the specific characteristics of HIV infection in AIDS stage, we opted for another treatment strategy in the second part of this work. This new therapeutic approach consists to introduce two controls, the first one characterizing the HAART and the other one characterizing the immunotherapy using interleukin-2 by tolerated doses, the introduction of this treatment combination has enabled us not only to maximize the number of healthy CD4
+ T-cells, reduce the level of infection and minimize treatment cost throughout the treatment period but it could also reduce the concentration of the HAART which allowed us to improve the patient's quality of life by reducing the side effects of heavy and continuous use of antiretroviral drugs.
